International Clinical Trial: An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07536815) titled 'An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)' on April 9.

Study Type: Expanded Access

Primary Sponsor: CytoDyn, Inc.

Condition: TNBC TNBC - Triple-Negative Breast Cancer TNBC, Triple Negative Breast Cancer

Intervention: Drug: leronlimab (PRO 140)

Recruitment Status: Not recruiting

Date of First Enrollment: June 1, 2025

To know more, visit https://clinicaltrials.gov/study/NCT07536815

Disclaimer: Curated by HT Syndication....